(May 10, 2012) In July 1999, the U.S. Food and Drug Administration (FDA) approved the drug pioglitazone, manufactured by Takeda and Eli Lilly and Company, as Actos, to help treat type 2 diabetic patients.
A two-year...
Actos Manufacturer Takeda Pharmaceuticals Gets $6.5 Million Actos Award Overturned
Actos, a highly controversial diabetes medication, has been linked to an increased risk of bladder cancer. The Japanese-based company Takeda Pharmaceuticals, which held a patent on Actos, is now facing 3,300 bladder cancer related suits.
The...
Adverse Events of Xarelto now Outnumber Pradaxa’s
Blood thinner, Xarelto, has surpassed its rival, Pradaxa, in both the number of prescriptions written and the number of severe adverse events reported by its users, according to the findings of a new analysis.
In the latest issue of...